ARB011 / Arbele - LARVOL DELTA

Pre-clinical development of ARB011: A CDH17 targeting allogeneic nonviral RNA-based "Flash" CAR-NK therapy for gastrointestinal cancer (AACR 2024) - "Moreover, engineering NK cells with nonviral CAR-encoding mRNA would provide a rapid large-scale manufacturing platform with minimal risk of abnormal genetic alteration mediated by viral integration. To generate the ARB011 CAR-NK cells, ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were electroporated with mRNA encoding a humanized anti-CDH17 scFv fused with transactivation domains. Overall, the findings suggest that ARB011 could be a novel off-the-shelf, CAR-NK therapy that warrants further studies in animal models and in clinical trials."

IO biomarker • Preclinical • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor • CDH17 • IFNG • LAMP1 • TNFA